About Us

Cell & Gene Therapy Consultancy

For Academic-to-Seed Translation

Our Beliefs

We believe stem cell therapy is the answer to so many disorders, therefore, should be available to all

We believe stem cell therapy is the answer to so many disorders, therefore, should be available to all

You are a researcher, an investor, or an executive? If so, POTENTCELLS services are a good fit for you

POTENTCELLS offer Stem Cell Therapy consultation and capacity building services that are customized to your project. Whether you are just starting to develop a process, or are gearing up for GMP production, we can help you achieve your goals

Mission

To be a globally recognized and nationally integrated leader in advancing cellular therapies

Vision

To enable investigators to deliver innovative cellular therapeutics through consultations, access to know-how, and sharing of expertise

Our Story

Many of the brilliant innovators that I met over the years share three concerns, regulatory, technical, and commercial. These three areas are constantly changing just as the CGT field is constantly evolving. 86% of academic CGT discoveries never reach clinical development, not because the science fails, but because the operational translation between academia and industry is broken. University technology transfer offices (TTOs) are overwhelmed, and other consultancies have a different focus. Investors see promising science wrapped in an incomplete, uninventable package. Therefore, I established POTENTCELLS to fill that gap; from our base in Saudi Arabia by serving academic labs globally.

We are the only consultancy built exclusively to close the academic‑to‑seed gap in cell and gene therapy (CGT). Our services cover CAR‑T, gene editing, and other advanced therapy medicinal products.

Naseem A. Almezel, CEO

What we do differently

  • CGT‑only focus: no small molecules, antibodies, or devices. Only cell and gene therapy.
  • Operational depth: regulators, executives, and academic PIs on our team.
  • Seed‑stage economics: no equity and no minimum engagement.
  • Implementation: we stay through CDMO selection, quality systems, and IND compilation.

Our track record

  • Trusted by academic, public, and private CGT programs 
  • 1st to serve CGT programs in Saudi Arabia and the region

Who we serve

  • Principal Investigators: get a clear translation roadmap
  • TTOs: on‑call CGT expertise via retainer
  • Early‑stage investors: due diligence and portfolio acceleration
  • Executives: get CGT technical clarity and leadership via fractional Chief Technology Officer

More About Naseem

POTENTCELLS founder and CEO, Naseem Almezel, earned his Master of Science degree in Cellular Therapies in 2010, since then his career focus is to support Bone Marrow Transplant and Oncology programs. Prior to POTENTCELLS, Mr. Almezel was the supervisor of the Cellular Manipulation Lab at Cincinnati Children’s Hospital Medical Center (U.S.A), where he oversaw the implementation of CART multiple myeloma therapy and sickle cell therapy gene transfer in CD34 production. Earlier, Mr. Almezel was a research assistant where he developed anti-viral cytotoxic T Cells for the Regenerative Medicine and Cellular Therapy at University of Cincinnati (UC) and held a Clinical Lab Scientist-Advanced and Manager positions at UC (U.S.A) where he led the implementation of the first Immunotherapy in U.S. Midwest. Mr. Almezel holds a M.Sc. degree in Cellular Therapies from the University of Cincinnati, and B.Sc. degree in Clinical Laboratory Sciences from King Saud University.